AG-FINASTERIDE
As listed in the register: AG-FINASTERIDE
5 mg · tablet
- Prescription only
- Urinary and reproductive system, hormones
- Active substance
- Finasteride
- Made by
- Angita Pharma Inc.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Finasteride). It describes the substance, not this exact product.
The development and enlargement of the prostate gland is dependent on the potent androgen, 5α-dihydrotestosterone (DHT).
Type II 5α-reductase metabolizes testosterone to DHT in the prostate gland, liver and skin.
Finasteride is extensively metabolized in the liver, primarily via the cytochrome P450 3A4 enzyme subfamily.
Following an oral dose of 14 C-finasteride in man (n=6), a mean of 39% (range, 32 to 46%) of the dose was excreted in the urine in the form of metabolites; 57% (range, 51 to 64%) was excreted in the feces.
Bioavailability of finasteride was not affected by food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-09
Safety of the active substance
From the US prescribing label for the same active substance (Finasteride). It describes the substance, not this exact product.
- Finasteride tablets are contraindicated in the following: Hypersensitivity to any component of this medication.
- Finasteride use is contraindicated in females when they are or may potentially be pregnant.
- Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant female who receives finasteride.
- Hypersensitivity to any components of this product (4).
The most frequently reported adverse reactions were related to sexual function. 3.7% (57 patients) treated with finasteride and 2.1% (32 patients) treated with placebo discontinued therapy as a result of adverse reactions related to sexual function, which are the most frequently reported adverse reactions.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States30 matching products
Spain28 matching products
- FINASTERIDA TARBIS 5 mg · comprimido recubierto con película2 makers
- ARAHORMO 5 mg finasterida · comprimido recubierto con película
- FINASTERIDA ALMUS FINASTERIDA 5 mg · comprimido recubierto con película
- FINASTERIDA ALTER 5 mg finasterida · comprimido recubierto con película
- FINASTERIDA ARAFARMA GROUP 5 mg finasterida · comprimido recubierto con película
- FINASTERIDA ARISTO 5 mg · comprimido recubierto con película
- FINASTERIDA AUROBINDO 5 MG · comprimido recubierto con película
- FINASTERIDA AUROVITAS 5 mg · comprimido recubierto con película
Netherlands8 matching products
- Proscar 5 mg 5 mg · filmomhulde tablet2 makers
- Finasteride 5 mg Teva 5 mg · filmomhulde tablet
- Finasteride Accord 5 mg 5 mg · filmomhulde tablet
- Finasteride Amarox 5 mg filmomhulde tabletten 5 mg · filmomhulde tablet
- Finasteride Aristo 5 mg filmomhulde tabletten 5 mg · filmomhulde tablet
- Finasteride Aurobindo 5 mg 5 mg · filmomhulde tablet
- Finasteride Mylan 5 mg 5 mg · filmomhulde tablet
SwitzerlandNo exact match for this strength and form
Details
| Made by | Angita Pharma Inc. |
|---|---|
| Active substance | Finasteride |
| Used in | Urinary and reproductive system, hormones |
| Strength | 5 mg |
| Form | tablet |
| Classification | G04CB01 · Urinary and reproductive system, hormones |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Dormant |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02374404 |
| DPD drug code | 85961 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.